SURVEILLANCE data from Week 29 ending July 25, 2026, confirm ongoing Candida auris clinical cases across the United States, highlighting a persistent public health challenge in acute and long term care facilities. A comprehensive review of eighty studies reveals that Candida auris exhibits clade dependent geographic distribution and resistance profiles. Clade I from South Asia and Clade III show fluconazole resistance rates exceeding 90%, whereas Clade IV demonstrates 44% resistance. Furthermore, amphotericin B resistance ranges up to 46% in Clade I, and echinocandin resistance varies significantly across lineages. The emergence of pan-resistant strains refractory to all three major antifungal classes poses a severe clinical threat, with 30-day mortality rates ranging between 23% and 67%.
A major driver of persistent colonization and nosocomial spread is the capacity of Candida auris to form resilient biofilms on medical devices and hospital surfaces. Biofilm-associated sessile cells display minimum biofilm eradication concentrations two to 4,119 times higher than planktonic minimum inhibitory concentrations. To combat these resistant reservoirs, novel antifungal agents show promising in vitro activity. Manogepix demonstrates the highest overall antibiofilm activity with a geometric mean eradication concentration of 5.9 micrograms per milliliter, while ibrexafungerp exhibits superior efficacy against Clade IV biofilms. Additionally, rezafungin offers extended half-life advantages for systemic management, providing crucial therapeutic alternatives for managing multidrug resistance.
Mitigating healthcare-associated Candida auris outbreaks requires rapid diagnostic identification and a tiered infection prevention framework. Conventional biochemical systems frequently misidentify Candida auris as related species, making updated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and molecular quantitative PCR assays essential for early detection. Tier one core measures mandate immediate multidisciplinary response activation, single-room isolation or cohorting, and strict alcohol-based hand hygiene. Tier two enhanced measures incorporate active composite swab screening of axilla and groin sites alongside daily environmental decontamination using sodium hypochlorite at 1,000 parts per million. Finally, tier three adjunctive strategies emphasize prospective antifungal stewardship to optimize echinocandin usage and prevent resistance selection.
Reference
Du X et al. Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks. Front Cell Infect Microbiol. 2026;16:1873741.
Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS) Weekly Data: Candida auris, Clinical (Week 29). CDC. 2026. Available from: https://www.cdc.gov
Featured Image: NAMPIX on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
